nach oben

Drugs

Erschienen in:

01.06.2001 | Adis New Drug Profile

Barnidipine

verfasst von: Harinder S. Malhotra, Greg L. Plosker

Erschienen in: Drugs | Ausgabe 7/2001

Einloggen, um Zugang zu erhalten

Abstract

▴ Barnidipine is an antihypertensive drag belonging to the dihydropyridine (DHP) group of calcium antagonists. It is available in a modified-release formulation which has a gradual onset of action and is effective in a single daily oral dose of 10 to 20mg.
▴ Barnidipine has selective action against cardiovascular calcium antagonist receptors and its antihypertensive action is related to the reduction of peripheral vascular resistance secondary to its vasodilatory action.
▴ The clinical antihypertensive efficacy of barnidipine is similar to that of other DHP calcium antagonists such as nitrendipine and amlodipine, and antihypertensives belonging to other drag classes such as atenolol and enalapril.
▴ Barnidipine has been found to be as efficacious and well tolerated as hydrochlorothiazide in the management of hypertension in elderly patients.
▴ Barnidipine is generally well tolerated. As with other DHP calcium antagonists, vasodilator adverse events such as headache, flushing and peripheral oedema account for most of the adverse events reported with its use and are usually transient. Oedema is less frequent than with amlodipine and nitrendipine. Its use is not associated with reflex tachycardia.

Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999 Sep 4; 319: 630–5PubMedCrossRef

Alderman M, Arakawa K, Beilin L, et al. 1999 World Health Organization — International Society of Hypertension Guidelines for the Management of Hypertension. Blood Press 1999; 8 Suppl. 1: 9–43

Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Drugs 1999 Oct; 58: 579–87PubMedCrossRef

Yamada S, Matsuoka Y, Kato Y, et al. A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats. J Pharmacol Exp Ther 1992 Aug; 262: 589–94PubMed

Yamada S, Matsuoka Y, Kimura R. Correlation between the plasma concentration of mepirodipine and its occupancy of Ca2+ antagonist receptors in rats. Pharm Res 1993 Sep; 10: 1346–9PubMedCrossRef

Inagaki O, Asano M, Takenaka T. In vitro and in vivo vasodilatory activity of barnidipine and its enantiomers. Biol Pharm Bull 1999 Feb; 22: 151–6PubMedCrossRef

van-der-Lee R, Kam KL, Pfaffendorf M, et al. Differential time course of the vasodilator action of various calcium antagonists. Fundam Clin Pharmacol 1998; 12: 607–12PubMedCrossRef

VasextenTM monograph. Yamanouchi Europe B.V

Noda H, Fujita T, Ogata E. The role of renal hemodynamics in the antihypertensive action of mepirodipine, a new calcium antagonist. Jpn Circ J 1992 Jan; 56: 21–6PubMedCrossRef

10.

Argenziano L, Izzo R, Iovino G, et al. Distinct vasodilation, without reflex neurohormonal activation, induced by barnidipine in hypertensive patients. Blood Press Suppl 1998; 1: 9–14PubMed

11.

Ohya Y, Abe I, Ohta Y, et al. Natriuretic effect of barnidipine, a long-acting dihydropyridine calcium channel blocker, in patients with essential hypertension. Int J Clin Pharmacol Ther 2000 Jun; 38: 304–8PubMed

12.

Motomura S, Hashimoto K. Reconsideration of vascular selectivity of dihydropyridine calcium antagonists: comparison of cardiovascular profile of mepirodipine, a novel dihydropyridine consisting of a single stereoisomer with (+)-(S)-(S) conformation, with those of nifedipine and nicardipine. Jpn J Pharmacol 1990 Feb; 52: 319–30PubMedCrossRef

13.

Kimura K, Suzuki N, Mise N, et al. Effects of barnidipine hydrochloride, a calcium channel blocker, on renal microcirculation in rats: A pilot study. Curr Ther Res Clin Exp 1998; 59(12): 826–34CrossRef

14.

Hashimoto M, Yamauchi T, Ogura T, et al. Treatment with a Ca(2+) channel blocker, barnidipine, reduces platelet-derived growth factor B-chain mRNA in glomeruli of spontaneously hypertensive rats. Am J Nephrol 1999; 19: 615–21PubMedCrossRef

15.

Kosegawa I, Inaba M, Morita T, et al. Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens 1998 Oct; 20: 751–61PubMedCrossRef

16.

Sakai T, Teramura T, Okamiya H, et al. A review on barnidipine: a novel calcium antagonist. Cardiovasc Drug Rev 1997; 15(4): 273–90CrossRef

17.

Teramura T, Watanabe T, Higuchi S, et al. Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. Xenobiotica 1997 Feb; 27: 203–16PubMedCrossRef

18.

Teramura T, Tokunaga T, Matsumoto H, et al. Metabolism of barnidipine hydrochloride, a potent calcium antagonist, in rat and dog. Xenobiotica 1996 Feb; 26: 177–87PubMedCrossRef

19.

Teramura T, Fukunaga Y, Van-Hoogdalem EJ, et al. Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica 1997 Sep; 27: 885–900PubMedCrossRef

20.

Hart W, Holwerda NJ. Barnidipine, a novel calcium antagonist for once-daily treatment of hypertension: a multicenter, double-blind, placebo-controlled, dose-ranging study. Dutch Barnidipine Multicenter Study Group. Cardiovasc Drugs Ther 1997 Nov; 11: 637–43PubMedCrossRef

21.

Smilde JG. The long-term efficacy and safety profile of barnidipine. Int J Clin Pract 2000 Nov; 114 Suppl.: 20–6

22.

Imai Y, Abe K, Nishiyama A, et al. Evaluation of the antihypertensive effect of barnidipine, a dihydropyridine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24h, daytime, and nighttime. Barnidipine Study Group. Am J Hypertens 1997 Dec; 10 (12 Pt 1): 1415–9

23.

Smilde JG, Holwerda NJ, Lustermans FAT. Impact of barnidipine on 24-hour ambulatory blood pressure in patients with mild to moderate esential hypertension. J Hypertens 2000 Jun; 18 Suppl. 2: 56

24.

Huh WS, Kim YS, Han JS, et al. Antihypertensive efficacy and tolerability of barnidipine hydrochloride in patients with renal parenchymal hypertension. Curr Ther Res Clin Exp 2000 Jul; 61: 395–405CrossRef

25.

Spieker C. Efficacy and tolerability of once-daily barnidipine in the clinical management of patients with mild to moderate essential hypertension. Blood Press Suppl 1998; 1: 15–21PubMedCrossRef

26.

Ruilope LM, Coca A. The role of combination therapy in the treatment of hypertension. Blood Press Suppl 1998; 1: 22–6PubMed

27.

Otterstad JE, Ruilope LM. Treatment of hypertension in the very old. Int J Clin Pract 2000 Nov; 114 Suppl.: 10–9

28.

Naber FB, Hage R, Mortelmans J. Barnidipine monotherapy and combination therapy in older patients with essential hypertension: a long-term study. Int J Clin Pract 2000 Nov; 114 Suppl.: 27–35

29.

van-der-Velden JW, Beudeker HJ, Nishi M. Diversity and intensity of adverse events in the treatment of hypertension with barnidipine. Blood Press Suppl 1998; 1: 27–9PubMedCrossRef

Titel: Barnidipine
verfasst von: Harinder S. Malhotra
Greg L. Plosker
Publikationsdatum: 01.06.2001
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 7/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200161070-00007

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Barnidipine

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2001

Chemoprevention of Breast Cancer with Fenretinide

Strategies for the Treatment of Cancer Pain in the New Millennium

Newer Neuromuscular Blocking Agents

Barnidipine

Alendronate

Monotherapy versus Combination Therapy as First Line Treatment of Uncomplicated Arterial Hypertension